Brief: Geneuro Enrolls First Patient In Temelimab Phase 2 Multiple Sclerosis Trial

Geneuro SA

25/06/2020 06:34

June 25 (Reuters) - Geneuro SA  GNRO.PA :
    * GENEURO ENROLLS FIRST PATIENT IN TEMELIMAB PHASE 2 MULTIPLE SCLEROSIS
TRIAL IN
COLLABORATION WITH THE KAROLINSKA INSTITUTET’S ACADEMIC SPECIALIST CENTER (ASC)
    * GENEURO SA - ONE-YEAR SINGLE CENTER TRIAL IS PLANNED TO ENROL 40 PATIENTS
WHOSE
DISABILITY PROGRESSES WITHOUT RELAPSES, KEY UNMET MEDICAL NEED IN MULTIPLE
SCLEROSIS 
    * GENEURO SA - START OF THIS PHASE 2 TRIAL HAD BEEN POSTPONED DUE TO
COVID-19
PANDEMIC
    * GENEURO SA - TRIAL RESUMED PROMPTLY AFTER SITUATION ALLOWED, AND RESULTS
REMAIN
EXPECTED IN H2 2021
    * GENEURO SA - THANKS TO KAROLINSKA INSTITUTET, TRIAL RESUMED PROMPTLY AFTER
SITUATION ALLOWED, AND RESULTS REMAIN EXPECTED IN SECOND HALF OF 2021

Source text for Eikon:  ID: 
Further company coverage:  GNRO.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))